- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jessica Hergert | Authors
Survival Boost Noted With Addition of Durvalumab to Chemotherapy for BTC
January 19, 2022
When compared with placebo and chemotherapy, durvalumab plus gemcitabine and cisplatin was superior in terms of overall survival in the treatment of advanced biliary tract cancer.
Cevostamab Becomes More Efficacious With Double Step-Up Dosing in Pretreated R/R Myeloma
December 15, 2021
Patients with heavily pretreated relapsed/refractory multiple myeloma achieved promising benefit in terms of cytokine release syndrome mitigation via double cycle 1 step-up dosing for cevostamab.
No Improvement in EFS for Aggressive B-cell NHL Noted With Second-line Tisagenlecleucel
December 13, 2021
Patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma did not benefit in terms of event-free survival when treated with the CAR T-cell therapy tisagenlecleucel vs standard-of-care chemotherapy and transplant.
Real-World Results for Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Hold Up to JULIET Data
December 12, 2021
Treatment with the CAR T-cell therapy tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma was favorable in both the pivotal clinical trial and the real-world setting, according to new data made available during 2021 ASH.
Venetoclax-Based Combos Demonstrate High Rates of uMRD in Frontline CLL
December 11, 2021
High rates of undetectable minimal residual disease were found in fit patients with chronic lymphocytic leukemia who were treated with venetoclax plus either obinutuzumab or ibrutinib vs chemoimmunotherapy.
AI and Palbociclib Followed By Fulvestrant Plus Palbociclib Doubled PFS for Hormone Receptor+, HER2- Metastatic Breast Cancer
December 07, 2021
Fulvestrant plus palbociclib after aromatase inhibitor plus palbociclib led to improvements in progression-free survival for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
TP53 and IGHV Continue to Demonstrate Utility as Predictive Markers of Response in CLL
October 23, 2021
In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in chronic lymphocytic leukemia.
Durvalumab Demonstrates Real-World PFS Benefit In Unresectable Stage III NSCLC
September 22, 2021
Findings from the PACIFIC-R trial indicated that the real-world progression-free survival benefit of durvalumab was higher vs the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.
Reduction In Disease Recurrence, Death With Adjuvant Pembrolizumab Noted in Resected High-Risk Stage II Melanoma
September 18, 2021
The use of adjuvant pembrolizumab resulted in a recurrence-free survival benefit for patients with resected high-risk stage II melanoma.
Nivolumab Plus Ipilimumab Demonstrate Continued Survival Benefit in All Subgroups in Unresectable Malignant Pleural Mesothelioma
September 18, 2021
Findings from the phase 3 CheckMate 743 trial indicated that patients with unresectable malignant pleural mesothelioma derived a continued overall survival benefit after being treated with nivolumab and ipilimumab.